Target intelligence / Profile preview

Opsin 1, short-wave-sensitive (blue cone photoreceptor pigment) (OPN1SW)

Target
OPN1SW
Molecular classification
G protein-coupled receptor, Rhodopsin-like receptor, Opsin family, Visual pigment
01

Overview

Opsin 1, short-wave-sensitive (OPN1SW) is a **G protein-coupled receptor** located in the cone cells of the human retina and is responsible for the absorption of **short-wavelength (blue/violet) light**, enabling blue color vision[2][3][5][10]. OPN1SW is essential for normal color discrimination and initiates phototransduction by triggering a signaling cascade upon light absorption in “S” (short-wavelength) cones[2][3]. Mutations in OPN1SW are associated with **tritanopia**, a rare form of inherited color vision deficiency characterized by the inability to distinguish blue from yellow, and with less severe abnormal S-cone function known as tritanomaly[2][5]. The molecule is classified in the rhodopsin-like GPCR family and shares structural properties with other opsins but is specifically tuned to blue light[1][5]. No approved drugs target OPN1SW, but molecular and genetic tests are available for research and clinical diagnostics of related color vision deficiencies[2][5].

Other names
Blue cone photoreceptor pigmentBlue cone pigmentBlue-sensitive opsinS cone pigmentBOPBCPOPSIN 1, SHORT-WAVE-SENSITIVEOPSB_HUMANOpsin 1 (cone pigments), short-wave-sensitiveS-pigmentShort-wave-sensitive pigment
02

Mechanism of action

Not applicable (no known drugs targeting OPN1SW); opsin function is intrinsic to visual signaling and not the current subject of drug modulation

03

Biological functions

Photoreceptor activity (light absorption in cone cells)Signal transductionCellular response to light stimulusDetection of blue/violet lightColor vision
04

Disease associations

Color vision deficiency (specifically tritan defects: tritanopia, tritanomaly)Other forms of hereditary color blindness
05

Safety considerations

Gene therapy and precision medicine challenges (related to delivery, expression, and immune responses if ever developed for OPN1SW-linked color blindness)No established drug safety concerns (as OPN1SW is not a pharmacological target)
06

Interacting drugs

None approved or established. Opsins are not typical direct therapeutic drug targets; no pharmacological agents currently interact with OPN1SW directly in clinical practice
07

Biomarkers

Genetic mutations in OPN1SW (used for diagnosis of tritan color vision deficiency/tritanopia)Altered S cone function (assessed via retinal imaging and function testing)Gene sequencing in color blindness panels

Beyond the preview

Go deeper on Opsin 1, short-wave-sensitive (blue cone photoreceptor pigment) (OPN1SW).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Opsin 1, short-wave-sensitive (blue cone photoreceptor pigment) (OPN1SW).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call